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Detection of a human intracisternal retroviral particle associated
with CD41 T-cell deficiency
(Pneumocystis carinu pneumonia/human immunodefidency virus-negative AIDS)
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ABSTRACT A number of non-human-mu eienc-
virus (HIV) type 1 disorders are associated with CD4+ T-cell
deficiency and dysfunction. However, the etiopathogenesis of
CD4+ T-cell immunodeficiency in these disease states remains
unclear. Human in sternal retroviral (HICRV) particles
were detected in a lymphoblastoid cell line exposed to mononu-
clear cells from a patient with severe CD4+ T-cell deficiency
without risk factors for HIV infection. Ultrastructurally, the
HICRV is distinct from HIV-1i, HIV-2, human T-lymphotropic
virus (HITLV) type I, and HTLV-II. Supernatants of activated
mononuclear cells showed ificant reverse trunscriptase ac-
tivity that was predominantly Mn2+ dependent. The patient's
mononuclear cells were negative for HIV-1, HIV-2, HTLV-I,
and HTLV-i proviruses as demonstrated by the lack of ampli-
fication by PCR. Also, the patient's serum was negative for
antibodies to HIV-1, HTLV-I, and HTLV-iH and for HIV-1 p24
antigen; however, serum was positive for antibodies against the
HICRV as demonstrated by Western blot. Similar HICRV
particles were detected in a lymphoblastoid cell line exposed to
mononuclear cells from the patient's daughter, who showed
CD4+ T-cell dysfunction. The HICRV may be associated with
CD4+ T-cell immunodeficiency and dysfunction in patients
without risk for HIV-1, HIV-2, HTLV-I, and HTLV-U.
Human retroviruses are associated with several human dis-
eases that involve disturbances of the growth of CD41 T
lymphocytes (1). Human T-lymphotropic virus (HTLV) type
I is associated with malignant expansion of CD41 T cells (2),
whereas human immunodeficiency virus (HIV) type 1 is
associated with depletion ofCD41 T cells, resulting in AIDS
(3-5). Recently, a human intracisternal A-type retroviral
particle was isolated from lymphoblastoid cells exposed to
homogenates of salivary gland from Sjogren syndrome (6).
The latter virus was antigenically related to HIV-1 p24. No
relationship to CD4+ T-cell deficiency was reported. A
number of non-HIV-1 disease states are associated with
CD4+ T-cell deficiency (7-17). Jacobs et al. (18) have de-
scribed a cluster of HIV-1-negative patients with Pneumo-
cystis carinji pneumonia without predisposing illness, some
ofwhom had T-cell defects. More recently, Gautier et al. (19)
reported three cases ofP. carinji pneumonia associated with
CD4+ T-cell deficiency. No HIV-1 antibody or HIV-1 antigen
was found during 1 year of follow-up. However, the etio-
pathogenesis of immune deficiency in these subjects remains
unclear. In the present report, we demonstrate the presence
of a human intracisternal retroviral (HICRV) particle in a
lymphoblastoid cell line (H9) and in peripheral blood mono-
nuclear cells (MNC) from a healthy control that were ex-
posed to MNC from a 66-year-old patient who had a severe
CD4+ T-cell deficiency (Table 1) and P. carinji pneumonia
but had no risk factors for HIV infection. Similar HICRV
particles were demonstrated in cocultures ofH9 cells and the
MNC of this patient's asymptomatic daughter who displayed
CD4+ T-cell dysfunction. Ultrastructurally, enzymatically,
antigenically, and by PCR, HICRV is distinct from HIV-1,
HIV-2, HTLV-I, HTLV-II, and from the human intracister-
nal A-type retroviral particle.
MATERIALS AND METHODS
Materials. Recombinant interleukin-2 (rIL-2) was pur-
chased from Amgen. A thermal cycler, primers SK145,
SK431, SK43, and SK44, and a GeneAmp PCR kit were
purchased from Perkin-Elmer/Cetus. Synthetic templates,
dT12_18-poly(rA) and dG12.18-poly(rC), for reverse transcrip-
tase (RT) activity were purchased from Pharmacia. U1 cells,
a subclone of U937 cells that were infected with HIV-1 (20),
and MT-2 cells (21), a T-cell line infected with HTLV-I, were
obtained from AIDS Research and Reference Reagent Pro-
gram (National Institute of Allergy and Infectious Diseases,
Bethesda, MD). Monoclonal antibodies to HIV-1 p24 were
purchased from Dako (Carpinteria, CA). Western blot de-
tection kits were purchased from Amersham.
Coculture of Patient's MNC with H9 Cells and MNC from
Controls. MNC (2 X 106 per ml) from the patient (no. 200) were
suspended in RPMI 1640 supplemented with penicillin (100
units/ml), streptomycin (100 pg/ml), 2 mM L-glutamine, and
10% heat-inactivated fetal calfserum, hereafter termed culture
medium, and cultured with phytohemagglutinin (PHA) P at 10
pg/mi for 72 hr at 370C in a 5% C02/95% air atmosphere. The
medium was then changed, and cells were resuspended in
culture medium containing rIL-2 at 10 units/ml. At day 7, cells
were cocultured with H9 cells orMNC from a healthy control
that were preactivated with PHA for 3 days, at a ratio of 1:3
(patient/H9 MNC or patient/normal control MNC). The cul-
ture medium was changed every 3 days, and cells were ex-
amined for syncytia formation and cell viability. After 3 weeks
of culture, cells were analyzed for virus particles by electron
microscopy. For RT activity, supernatants were collected at
various time intervals from PHA- plus rIL-2-activated MNC
ofthe patient and cocultures ofthe patient'sMNC and H9 cells
(H9/200) and frozen at -700C until analyzed.
Electron Microscopy. Cells were pelleted, fixed in cold
2.5% glutaraldehyde in 0.12 M phosphate buffer (pH 7.4) for
30 min, and rinsed in buffer prior to postfixation in 1%
osmium tetroxide for 30 min. The pellets were embedded in
4% Bacto-agar solution to hold them together during pro-
cessing. Blocks were made by using a razor blade and
dehydrated with ethyl alcohol and propylene oxide before
being embedded in Medcast. Ultrathin sections of these
Abbreviations: HIV, human immunodeficiency virus; HTLV, hu-
man T-lymphotropic virus; PHA, phytohemagglutinin; rIL-2, recom-
binant interleukin 2; HICRV, human intracisternal retrovirus; MNC,
peripheral blood mononuclear cells; RT, reverse transcriptase; SSV,
simian sarcoma virus.
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Table 1. Immunological analysis of the patient (no. 200)
Value
Tests Patient Control
Lymphocyte subset, numbers (%)
CD2+ T cells 1041 (61) 1467-3003 (65-85)
CD3+ T cells 857 (52) 1277-2929 (59-76)
CD4+ T cells 171 (10) 782-1626 (32-47)
CD8+ T cells 700 (50) 463-1369 (24-36)
CD4+/CD8+ ratio (0.2) (0.9-2.1)
CD20+ B cells 290 (17) 163-411 (4.6-16.8)
CD25+ T cells (72.1) (54-78)
DNA synthesis, cpm
Mitogen
PHA (10 pLg/ml) 4605 67,523-122,813
Con A (10 pug/ml) 2064 21,286-62,700
Pokeweed mitogen (1:400) 2763 14,220-39,400
Antigen
Mumps 233 4,850-24,329
Candida albicans 214 13,357-35,574
Tetanus toxoid 115 3,945-27,193
Purified protein derivative 270 0-406
Serum immunoglobulins, mg/dl
IgG 1010 723-1685
IgM 93 63-277
IgA 88 69-382
Antibody and antigen status
Anti-HIV-1 antibodies Neg Neg
HIV-1 p24 antigen Neg Neg
Anti-HTLV I and
anti-HTLV II antibodies Neg Neg
Lymphocyte subsets were analyzed with monoclonal antibodies,
using FACScan. CD25+ (Tac/IL-2 receptor) T cells represent per-
cent of cells positive for CD25 antigen on mononuclear cells preac-
tivated with PHA for 3 days. Serum anti-HIV 1 antibodies were
assayed by ELISA and Western blot. Serum HIV-1 p24 antigen was
measured by ELISA. Serum anti-HTLV I and anti-HTLV II anti-
bodies were assayed by an immunofluorescence technique. Neg,
negative.
embedded blocks were cut at a thickness of 50-60 nm,
contrast enhanced with uranyl acetate, and examined with a
Philips CM 10 electron microscope.
RT Activity. Supernatants of PHA- plus rIL-2-activated
MNC of the patient and H9/200 cells were collected at
various time intervals and examined for precipitable RT
activity. Supernatants were centrifuged at 10,000 x g for 15
min and treated with polyethylene glycol 8000 [30%o (wt/vol)
with 0.4 M NaCl]. The mixture was maintained overnight at
4°C. All specimens were centrifuged at 10,000 x g for 45 min
at 4°C. Supernatants were discarded, and pellets were resus-
pended in 100 ,ul of buffer containing Triton X-100. Speci-
mens were frozen at -70°C until analyzed. Negative controls
consisted of supernatants ofPHA- plus IL-2-activated MNC
and the H9 cell line and medium alone. Positive controls
consisted of supernatants from HIV-1 (Mg2+-dependent RT)-
infected H9 cells and simian sarcoma virus (SSV) (Mn2+-
dependent RT). Precipitable RT activity was measured in the
presence or absence of Mn2+ (0.3 mM) or Mg2+ (10 mM) as
divalent cations and dT12.18 poly(rA) and dG12_18 poly(rC) as
synthetic primer templates (22). Data are expressed as cpm.
PCR for HIV and HTLV Proviruses. Genomic DNA was
prepared by the proteinase K/phenol extraction method (23)
from H9/200 cells, U1 (HIV-1-infected) cells, and MT-2
(HTLV-I-infected) cells. Genomic DNA from MNC of a
normal donor was used as a negative control. One-half
microgram of each DNA was used as template for PCR.
Primers SK145 and SK431 were designed to amplify DNA in
the gag region of both HIV-1 and HIV-2 proviruses. Primers
SK43 and SK44 were used to amplify DNA in the tax region
of both HTLV-I and HTLV-II proviruses. PCR was done
with a thermal cycler and GeneAmp PCR kit for 42 cycles of
1 min at 940C, 1 min at 600C, and 3 min at 720C. Amplified
DNA was analyzed with 2% agarose gel electrophoresis.
Amplified DNA was confirmed by Southern hybridization
analysis with SK102 and SK45 probes for HIV and HTLV
proviruses, respectively. To demonstrate the sensitivity of
our PCR assay, experiments were performed with DNA
isolated from U1 and MT-2 cells that were mixed with DNA
from normal peripheral blood lymphocytes to obtain the final
amount of DNA equivalent to that from 100%6, 10%6, 1%,
0.1%, and 0.01% infected cells.
Detection of Antibodies Against HICRV. Ten million H9
cells, H9/200 cells, HIV-1-infected H9 (H9/HIV-1) cells, and
MT-2 (HTLV-I-infected) cells were lysed in 500 .ul of lysing
buffer, and nuclear materials were removed by microcentrif-
ugation for 1 hr at 40C. One hundred microliters of superna-
tant was mixed with an equal volume ofsample loading buffer
(2% SDS/100 mM dithiothreitol/60 mM Tris-HCl, pH 6.8/
0.01% bromophenol blue), and 20 A of the sample (-29 jig
total protein) was applied to an SDS/PAGE (10%) gel.
Separated proteins were transferred to nitrocellulose paper
by using a Novex (Encinitas, CA) transfer apparatus. A
Western blot was probed with normal serum or the patient's
serum (1:50 dilution) preadsorbed with MNC from a healthy
donor. Proteins bound to serum antibodies were visualized
with alkaline phosphate-conjugated goat anti-human immu-
noglobulin and a blot detection kit. To demonstrate that the
precipitated bands in H9/200 cell lysates were not HIV-1, cell
lysates were also probed with monoclonal antibodies to
HIV-1 p24. The positive controls consisted of HIV-1 virus
lysates and lysates from H9/HIV-1 cells. The negative con-
trol consisted of uninfected H9 cells. Antibody-bound pro-
teins were visualized by a sequential treatment of biotiny-
lated anti-mouse immunoglobulin and alkaline phosphatase-
conjugated streptavidin, using a blot detection kit.
RESULTS
Electron Microscopy. Results of electron microscopic ex-
amination of H9 cells, H9/200 cells, and H9 cells cocultured
with the daughter's MNC are shown in Fig. 1. Fig. 1 A and
B shows the presence of viral particles in many cisternae of
H9/200 cells. No viral particles were seen in the nucleus. The
intracisternal viral particles were uniform in morphology,
=80 nm in diameter with two concentric rings of electron-
dense material and a clear center. The inner core was
considerably thicker than the outer layer. Spikes were also
noted on the outer surface. Twenty to 30 particles in each cell
were seen in individual thin sections. Control H9 cells
showed no viral particles (Fig. ID). Fig. 1C shows the
presence of similar intracisternal viral particles in cocultures
of H9 cells with MNC from the patient's daughter. In
addition, we have been able to transfer HICRV infection in
vitro (as determined by electron microscopy) from the MNC
of the daughter to MNC from a healthy control (data not
shown). Since progressive cell death was observed in cocul-
tures ofH9/200 (without syncytia formation), it was reasoned
that the virus must be released in the cultured medium. To
transfer the viral infection from culture supernatants to
normal MNC, supernatants from H9/200 cells were filtered
and centrifuged at 10,000 x g for 15 min to remove cellular
debris. Supernatants were then centrifuged at 40,000 x g for
8 hr at 40C, and pellets were used as virus inoculum to infect
PHA- plus rIL-2-activated MNC from a normal healthy
donor. After 2-3 weeks in culture, cells were examined with
an electron microscope. Intracisternal viral particles similar
to those seen in H9/200 cells were detected (data not shown).
RT Activity. Culture supernatants from the patient's MNC
stimulated with PHA plus rIL-2 were examined for precipi-
table RT activity in the presence or absence of divalent
Proc. Natl. Acad. Sci. USA 89 (1992)
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cations Mg2+ or Mn2+, using dT12_18poly(rA) and dG12_18
poly(rC) as synthetic templates. Fig. 2A shows a significant
RT activity that was predominantly Mn2+ dependent. At day
7 onward, progressive cell death was observed in cultures.
Similar Mn2+-dependent RT activity was observed in the
supernatant of HICRV-infected H9 cells (Fig. 2B). The
positive (SSV for Mn2+-dependent RT and HIV-1 for Mg2+-
dependent RT) and negative controls (MNC, H9, and me-
dium) for both experiments are shown in Fig. 2B.
PCR. To further distinguish HICRV from HIV or HTLV,
PCR analysis was performed with genomicDNA isolated from
H9/200 cells, U1 cells, and MT-2 cells. DNA from a normal
donor's mononuclear cells was used as a negative control. Fig.
3 shows that PCR failed to amplify HIV and HTLV proviruses
from genomic DNA of the patient's MNC, whereas 142-base-
pair and 159-base-pair DNA in U1 and MT-2 were amplified
from HIV and HTLV proviruses, respectively. The sensitivity
of our PCR technique was tested on DNA isolated from U1
, FIG. 1. Electron micrographs
ofH9 cells that were infected with
Z the patient's (A and B) or the
daughter's (C) mononuclear cells
and a control noninfected H9 cell
(D). (A) Part of a H9 cell that was
cocultured with the patient's
MNC (H9/200). Numerous virus
^*+Lg particles appear within cisterns
(arrows) in the cytoplasm but not
in the nucleus (N). (B) Enlarge-
ment of three virus particles found
in the cistern that is indicated at
the top of A. The virus particle
(arrow) displays two concentric
rings of electron-dense material
and a clear center. (C) Portion of
an H9 cell that was cocultured
t i, with MNC of the patient's daugh-
m ter. Note that these virus particles(arrows) have a morphology and
size similar to that for those found
in H9/200 cells. They are also
found within cisterns. (D) Control
H9 cell. It displays a normal-
w appearing nucleus (N) and a cyto-
plasm that lacks viral particles.
(The scale bar for D is the same
length as that inA; all scale bars =
.t,> G il ~~0.5 jim.)
and MT2 cells that were mixed with graded proportions of
DNA from normal MNC to obtain DNA equivalent to 100%,
10%, 1%, 0.1%, and 0.01% of infected cells. The PCR tech-
nique was sensitive in detecting a signal at the level of 0.01%
infected cells. These data suggest that HICRV is distinct from
HIV-1, HIV-2, HTLV-I, and HTLV-ll and that our patient is
not infected with HIV or HTLV.
Serum Antibodies Against HICRV. To determine whether
the patient has circulating antibodies against HICRV, her
serum was examined by Western blot assay. The Western
blot analysis of the patient's serum was performed by using
homogenates of H9, H9/200, H9/HIV, U937/HIV-2, and
MT-2 cells. A distinct band of =24 kDa was observed in
H9/200 cells but not in homogenates of H9, H9/HIV-1,
U937/HIV-2, and MT-2 cells (Fig. 4A). Normal serum
showed no band at 24 kDa (Fig. 4B). To determine and
exclude any possibility that the 24-kDa protein precipitated
from H9/200 cells is similar to HIV-1 p24, Western blots were
Medical Sciences: Gupta et al.
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FIG. 2. RT activity in supernatants of PHA- plus rIL-2-activated MNC of the patient (A) and in the supernatants from cell-free transmission
ofHICRV-infected H9 cells (B). Data are expressed as cpm after subtracting the background counts. Fig. 2A includes negative controls (H9, MNC,
and medium) and positive controls (SSV and H9/HIV-1) for Mn2+ with dGu.8Wpoly(rC) (Mn dGrC) and Mg2+ with dGuisrpoly(rC) (Mg dGrC).
Fig. 2B shows the negative (supernatants from uninfected H9 cells, activated MNC, and medium) and positive (supernatants from HIV-1-infected
H9 cells, and SSV) controls for Mn2+ with dTH12_1poly(rA) (Mn dTrA) and Mg2+ with dT12-jgpoly(rA) (Mg dTrA) for both experiments.
performed with lysates ofH9 cells (negative control), H9/200
cells, H9/HIV-1 cells (HIV-1 positive control), and HIV-1
virus lysates, using a monoclonal antibody to HIV-1 p24. No
reactions were observed between the anti-HIV-1 p24 mono-
clonal antibody and H9/200 or H9 cell lysates, but a positive
reaction was observed between anti-HIV-1 p24 and H9/
HIV-1 and HIV-1 virus lysates (Fig. 5). These data demon-
strate that the 24-kDa band in H9/200 cells is not shared by
HIV-1 p24. Therefore, HICRV p24 appears to be antigeni-
cally distinct from that of HIV-1. The data also show the
presence of antibodies in the patient's serum against the
24-kDa protein of HICRV.
DISCUSSION
In the present study we have isolated HICRV particles from
a 66-year-old patient with severe CD4+ T-cell deficiency and
P. carinji pneumonia and her 38-year-old asymptomatic
daughter with CD4+ T-cell dysfunction. Neither the patient
nor her daughter had any risk factors for HIV infection and
were negative for antibodies to HIV-1, HTLV-I, and HTLV-
II, and for HIV-1 p24 antigen. Furthermore, in the patient,
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PCR analysis failed to show infection with HIV-1, HIV-2,
HTLV-I, or HTLV-II.
Human retroviruses are associated with diseases com-
monly associated with altered growth of CD4+ T cells.
HTLV-I is associated with malignant expansion of CD4+ T
cells (2), whereas HIV-1 is associated with depletion ofCD4+
T cells, resulting in AIDS (3-5). The present patient had no
risk factors for HIV infection, and there was no serological
or PCR evidence of infection with HIV-1, HIV-2, HTLV-I,
or HTLV-II. Ultrastructurally, enzymatically, serologically,
and by PCR, HICRV is distinct from HIV-1, HIV-2, HTLV-I,
and HTLV-II. Recently, Garry et al. (6) isolated a human
intracisternal A-type retroviral particle from a- lymphoblas-
toid cell line exposed to homogenates of salivary gland from
Sjogren syndrome. It is unclear whether lymphocytes from
patients with Sjogren syndrome were infected with this virus.
Moreover, no association with CD4+ T-cell deficiency and
dysfunction was reported. Although ultrastructurally and
enzymatically HICRV is similar to the A-type intracisternal
retroviral particle, it is distinct from the intracisternal A-type
retrovirus as demonstrated by a lack of HIV-1 and HIV-2
proviruses in the patient's cells, a lack of reactivity of
anti-HIV-1 p24 antibody with the 24-kDa protein ofHICRV,
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FIG. 3. PCR for HIV and HTLV proviruses. (A) Primers SK145
and SK431 were designed to amplify DNA in the gag region of both
HIV-1 and HIV-2 proviruses. (B) Primers SK43 and SK44 were used
to amplify DNA in the tax region of both HTLV-I and HTLV-II
proviruses. No bands were observed with DNA from H9/200 and
peripheral blood mononuclear cells (PBMC) from normal control and
either sets of primers. Positive bands were observed with U1 and
MT-2 DNA, using respective primers for HIV-1 and HTLV-I. PCR
analyses were done using DNA extracted from 100%, 10%o, 1%,
0.1%, and 0.01% HIV-1-infected U1 and HTLV-I-infected MT-2 to
demonstrate the sensitivity of the assay. bp, base pair(s).
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FIG. 4. Western blot analysis of patient no. 200 (A) and normal
(B) serum against homogenates of H9, H9/HIV-1, MT-2, U937/
HIV-2, and H9/200 cells. A distinct band of -24 kDa was observed
between H9/200 cells and the patient's serum. The patient's serum
had no such reactivity with H9, H9/HIV-1, U937/HIV-2, or MT-2
homogenates. The normal serum had no reactivity at 24 kDa with any
of the cell line homogenates.
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FIG. 5. Western blot analysis of anti-HIV-1 p24 monoclonal
antibody against lysates from H9, H9/200, and H9/HIV-1 cells and
HIV-1 virus lysates. Anti-HIV-1 p24 reacted with H9/HIV-1 cell and
HIV-1 virus lysates but did not react with lysates from H9 or H9/200
cells.
and absence of serum antibodies against HIV-1 in the pa-
tient's serum. The A-type intracisternal retrovirus is anti-
genically related to HIV-1, and sera from patients with
Sjcgren syndrome are positive for HIV-1 antibodies.
In this study, we have shown the presence of circulating
antibodies in the patient's serum against a protein of :24 kDa
(likely Gag protein) by Western blot. Furthermore, this
24-kDa band is not recognized by monoclonal antibodies to
HIV-1 p24, suggesting that the HICRV 24-kDa protein is
antigenically distinct from that of HIV-1 p24. A cluster of
patients with P. carini pneumonia have been reported in
HIV-1-negative subjects without any predisposing factors
(18). More recently, Gautier et al. (19) have reported three
unusual cases ofP. carinji pneumonia associated with CD41
T-cell deficiency in whom there was no evidence of HIV-1
infection over a 1-year follow-up. Our present patient is
similar to those described by Gautier et al. Her immunode-
ficiency has persisted for the past 18 months. It is possible
that some of these patients with CD4+ T-cell deficiency and
dysfunction are infected with HICRV.
The mode of transmission of HICRV is presently unclear..
A possibility of transmission of HICRV through blood trans-
fusion is entertained. Our patient had a history of blood
transfusion in 1949-1950 for bleeding following a spontane-
ous abortion. HICRV also appears to be vertically transmit-
ted as demonstrated by the presence of HICRV particles in
H9 cells cocultured with the MNC from the daughter of the
patient. The daughter had normal proportions and numbers of
CD4+ T cells; however, a functional defect of CD4+ T cells,
as demonstrated by a poor proliferative response to soluble
antigens (Candida albicans, mumps, and tetanus toxoid) was
observed. The proliferative responses to mitogens (PHA,
Con A, and pokeweed mitogen) were normal. These immu-
nological abnormalities were reproducible over a 6-month
period (data not shown). A similar immunological profile has
been observed in early stages of HIV-1 infection (24, 25).
In summary, we have identified a human retrovirus
(HICRV) from a patient with CD41 T-cell deficiency and P.
carinji pneumonia and her asymptomatic daughter with
CD4+ T-cell dysfunction. HICRV is distinct from HIV-1,
HIV-2, HTLV-I, HTLV-II, and intracisternal A-type retro-
virus. The causal relationship of HICRV to CD41 T-cell
deficiency remains to be established. Additional modes of
transmission, cell tropism, receptor(s) for HICRV, etc. re-
main to be defined. A possibility of HICRV infection should
be entertained in patients with CD4+ T-cell deficiency and/or
dysfunction, with or without opportunistic infections, in
whom HIV and HTLV infections have been excluded.
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